by guojie | Jan 25, 2022 | Uncategorized
According to MyBio data statistics, totally 281 BD licensing deals occurred in 2021 in China pharmaceutical industry. 1. The 281 deals include 174 cross-border licenses and 107 licenses between Chinese bios. 2. The 174 cross-border licenses include 133 License-in... by guojie | Apr 1, 2021 | Uncategorized
MyBio Capital partner Dr. Ginger Ding hosted a fire chat session at China Focus Global Life Science Summit. Joining together are Jonathan Wang, CEO of Inmagene Biopharmaceuticals, Jimmy Zhang, CEO of AccuGen Group, John Zhu, Venture partner of 6 Dimensions... by guojie | Mar 31, 2021 | Insights
Author: Ginger Ding On September 4, 2020, I-Mab Biopharma announced a collaboration with AbbVie on the global development and commercialization of CD47 monoclonal antibody TJC4. The US$2.9 billion collaboration signifies the largest out-licensing in the history... by guojie | Mar 31, 2021 | Insights
Author: Ginger Ding The rate of return on investment in new drugs has steadily declined; it is imperative to improve R&D efficiency New drug research and development has three characteristics that may raise concerns: high cost (985.3 million [1]), a long... by guojie | Mar 31, 2021 | Insights
Bladder cancer occurs when cells that comprise the urinary bladder begin to grow out of control. Over time, as more cancer cells develop, they can form a tumor and spread to other parts of the body. The most common type of bladder cancer, according to the American...